BioSpace News Archive

Products in the global branched stent grafts market find applications in various EVAR or endovascular aneurysm repair procedures.

There is a rapid increase in the cases of brain aneurysms in different countries across the globe. The risk factors associated with these brain aneurysms are driving growth in the flow diverters market.

The fusion biopsy market is anticipated to observe steady growth during the forecast period of 2020-2030.

Medical protective equipment forms a core part of germ-protection measure adopted by healthcare workers in the treatment of infectious and communicable diseases.

OSE Immunotherapeutics announces the presentation of Phase 3 clinical results of Tedopi® at 13:30 CEST in a late-breaking oral presentation at the European Society for Medical Oncology Virtual Congress.

Bionomics Limited, a clinical-stage biopharmaceutical company, is pleased to announce that as part of its broader pipeline expansion strategy and based on anti-anxiety signals in Generalised Anxiety Disorder patients, it has decided to proceed with evaluating its lead clinical compound, BNC210, for acute treatment of Social Anxiety Disorder with a planned commencement of a clinical trial by the end of this year.

ChromaDex Corp. announced findings from recently published preclinical studies, as well as recently registered clinical research, investigating Niagen® in various health outcomes.

Immunocore Holdings Plc presented new data from the Company’s lead program, tebentafusp, at an oral presentation at the European Society for Medical Oncology Congress.

Gritstone bio, Inc. announced that the first volunteer has been dosed in a Phase 1 trial evaluating the ability of GRT-R910, a self-amplifying mRNA second generation SARS-CoV-2 vaccine to boost and expand the immunogenicity of first-generation COVID-19 vaccines in subjects 60 years of age or older.

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to announce that it plans to file a pre-IND meeting request with the U.S. Food and Drug Administration for an NP-120 Phase 2 chronic cough study.